^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FCRLA (Fc Receptor Like A)

    i
    Other names: FCRLA, Fc Receptor Like A, FCRL, FREB, Fc Receptor-Like A, FCRLc2, FCRLc1, FCRLM1, FCRLb, FCRLd, FCRLe, FCRLX, Fc Receptor-Like And Mucin-Like Protein 1, Fc Receptor Homolog Expressed In B-Cells, Fc Receptor-Like And Mucin-Like 1, Fc Receptor-Related Protein X, Fc Receptor-Like Protein, MGC4595, FCRL1, FCRX, Fc Receptor Homolog Expressed In B Cells (FREB), Fc Receptor Related Protein X, FcRX
    Associations

    News

    Trials
    13d
    Single cell atlas of the comorbidity mechanism between chronic obstructive pulmonary disease and lung adenocarcinoma: a study of multi-omics combined analysis. (PubMed, PeerJ)
    Several candidate drugs have been identified. FCRLA, GREM1, and MMP9 are inflammation-associated genes that may link the pathobiology of COPD and LUAD, and serve as valuable biomarkers with therapeutic potential in high-risk populations.
    Journal
    |
    MMP9 (Matrix metallopeptidase 9) • FCRLA (Fc Receptor Like A)
    6ms
    Targeting FCRLA to induce necrosis in lung adenocarcinoma: a novel strategy for prognosis and therapy via MPT-Driven pathways. (PubMed, Front Immunol)
    RASGRP2, CD79A, and FCRLA have been identified as being associated with MPTDN in LUAD cells. FCRLA knockdown may suppress mitochondrial permeability transition through specific pathways, thereby driving LUAD cell necrosis and providing potential targets for subsequent LUAD treatment.
    Journal
    |
    CD79A (CD79a Molecule) • FCRLA (Fc Receptor Like A)
    9ms
    TNFα activation of the PLEKHA5-FCRLA axis disturbs lipid metabolism, leading to the progression of cutaneous malignant melanoma. (PubMed, Lipids Health Dis)
    The predictive model of CMM related to lipid metabolism was constructed. TNFα activates the PLEKHA5-FCRLA axis to enhance neutral lipid storage and energy metabolism in CMM cells, promoting malignant behavior.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FCRLA (Fc Receptor Like A) • PRXL2B (Peroxiredoxin Like 2B)
    over1year
    Fc receptor-like A promotes malignant behavior in renal cell carcinoma and correlates with tumor immune infiltration. (PubMed, Cancer Med)
    Fc receptor-like A is positively correlated with poor outcomes in RCC patients and plays an oncogenic role in RCC through the pERK1/2-MMP2 pathway. Patients with RCC might benefit from immunotherapy targeting FCRLA.
    Journal • IO biomarker
    |
    MMP2 (Matrix metallopeptidase 2) • FCRLA (Fc Receptor Like A)
    over2years
    Metastatic triple negative breast cancer has distinct tumor immune landscape (SABCS 2023)
    Our comprehensive biomarker analyses showed that metastatic TNBC has a more inflamed tumor microenvironment and higher checkpoint target expression compared to non-TNBC. Further analysis of immune expression by site-specific metastases and correlation with immunotherapy outcomes is warranted to guide clinicians in selection of the ideal metastatic site to biopsy for therapeutic decision making. However, in a collective TNBC context, these data support the use of immunotherapy in metastatic TNBC.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • LAMP3 (Lysosomal Associated Membrane Protein 3) • GZMB (Granzyme B) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • KRT5 (Keratin 5) • PRF1 (Perforin 1) • FCRLA (Fc Receptor Like A) • ITGA1 (Integrin Subunit Alpha 1)
    |
    HER-2 overexpression
    |
    PD-L1 IHC 22C3 pharmDx
    over2years
    Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer. (PubMed, Cardiovasc Toxicol)
    Finally, we validated the expression level of immune-related genes in breast cancer patients-derived cardiomyocytes with doxorubicin-induced cardiotoxicity and found that the level of RAD9A, HSPA1B, GATA2, IGF2R, CD200, ERCC8, and BCL11A genes are consistently dysregulated. Our findings offered a basis for understanding the mechanism and pathogenesis of the cardiotoxicity caused by doxorubicin in breast cancer patients and predicted the interaction of immune-related potential biomarkers with doxorubicin.
    Journal • BRCA Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • BRCA (Breast cancer early onset) • BIRC3 (Baculoviral IAP repeat containing 3) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD200 (CD200 Molecule) • CD79A (CD79a Molecule) • GATA2 (GATA Binding Protein 2) • BTLA (B And T Lymphocyte Associated) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CPA3 (Carboxypeptidase A3) • FCRL1 (Fc Receptor Like 1) • LRP1 (LDL Receptor Related Protein 1) • MS4A1 (Membrane Spanning 4-Domains A1) • TCL1A (TCL1 Family AKT Coactivator A) • FCRLA (Fc Receptor Like A) • FCRLB (Fc Receptor Like B) • RAD9A (RAD9 Checkpoint Clamp Component A)
    |
    doxorubicin hydrochloride
    over2years
    Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer. (PubMed, Yi Chuan)
    These above results suggest that the risk score developed in this study can be utilized for predicting patients' prognosis and evaluating their immune infiltration status. This study can serve as a guide for subsequent tumor immunotherapy and gene targeting therapy.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • NT5E (5'-Nucleotidase Ecto) • PDGFB (Platelet Derived Growth Factor Subunit B) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • FCRLA (Fc Receptor Like A) • S100P (S100 calcium binding protein P) • TFAP2A (Transcription Factor AP-2 Alpha)
    almost3years
    GENE EXPRESSION PROFILING OF T(14;18)-NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESIS (ICML 2023)
    GEP identified two distinct groups within t(14;18)-neg FL, indicating different stages of differentiation of the neoplastic B cells. FLnegmut shows activation of STAT6 pathway through upregulation of CD23 and IL4R and by enrichment in GSEA and correlates with CD23 expression. Constitutive activation of STAT6 and consequent upregulation of CD23 prevent ongoing B cell differentiation in FLnegmut, precluding the cells from exiting the GC and adopting the state of activated B cell.
    IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF17 (TNF Receptor Superfamily Member 17) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • S100A8 (S100 Calcium Binding Protein A8) • IRF4 (Interferon regulatory factor 4) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • TYK2 (Tyrosine Kinase 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CD40 (CD40 Molecule) • FCGR1A (Fc Fragment Of IgG Receptor Ia) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • IL4 (Interleukin 4) • FCER2 (Fc Fragment Of IgE Receptor II) • FCRLA (Fc Receptor Like A) • IL4R (Interleukin 4 Receptor) • SLAMF7 (SLAM Family Member 7) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    SOCS1 mutation
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel